AstraZeneca's Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.

Sipavibart is an investigational long-acting antibody designed to provide COVID-19 protection for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.

When a cancer cell doesn't respond to traditional therapies, doctors may turn to a sort of viral biological warfare, by deploying 'troops' in the form of viral agents that are specifically engineered to target and eliminate cancer cells. The mode of attack is to transform the tumor into an immunologically "hot" environment, making it more visible and recognisable to our immune system.

FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info 6/28/2024

Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate 6/28/2024

ICER Doubles Down on Critique of Lykos’ MDMA Therapy, Cites Data Concerns 6/28/2024

FDA Needs to Step Up As Use of Third-Party Manufacturers Leads to Rejections 6/28/2024

With Latest Expansion in Ohio, Resilience Can Best Serve Partners and Patients 6/28/2024

Illumina Reports $1.47B ‘Goodwill’ Impairment Charge After Grail Spinoff 6/28/2024

AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff 6/28/2024

Antibiotic-resistant bacterial infections are becoming a major societal challenge. To solve this problem, researchers are working on new drugs that kill bacteria without developing resistance, and on new materials that prevent the formation of bacterial biofilms. The latter are the source of resistant variants but are notoriously difficult to remove. Recently, researchers from the Institute of Physical Chemistry, Polish Academy of Sciences have discovered that making the surface undulated can help limit the spread of resistant bacteria.

Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection 6/27/2024

Verona Wins FDA Approval for COPD Drug, Eyes Q3 Launch With $1B Financing for Rollout 6/27/2024

Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss 6/27/2024

AbbVie, Genmab Secure FDA Label Expansion for Epkinly in Follicular Lymphoma 6/27/2024

CDC Narrows RSV Vaccine Recommendations for Seniors 6/27/2024

New Team, Same Company: How to Transition to Your New Role 6/27/2024

Leadership Lab: 3 Strategies for an Executive’s Discreet Job Search 6/27/2024

5 Top Companies Hiring in the Washington, D.C., Area 6/27/2024

AlphaFold is an outstanding example of artificial intelligence's computational capabilities in accurately predicting intricate protein structures. A new Review article explores AlphaFold's recent advancements and its potential impact on predictive medicine. The article is published in the peer-reviewed journal AI in Precision Oncology.

Vivek Subbiah, MD, from the Sarah Cannon Research Institute, and coauthors, describe a shift toward predictive medicine,

Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate 6/26/2024